Navigation Links
Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:10/3/2007

SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to provide a corporate overview of its clinical development and discovery programs at two upcoming investor conferences:

-- Natixis Bleichroeder Hidden Gems Conference

Presentation: Monday, October 8, 2007 at 8:00 a.m. Eastern Time (5:00

a.m. Pacific Time) at the Carlton Hotel on Madison Avenue in New York

City

Presenting: Robert E. Hoffman, Arena's Vice President, Finance and

Chief Financial Officer

-- BIO InvestorForum 2007

Presentation: Wednesday, October 10, 2007 at 2:15 p.m. Pacific Time

(5:15 p.m. Eastern Time) at the Palace Hotel in San Francisco

Presenting: Louis J. Scotti, Arena's Vice President, Marketing and

Business Development

A live audio webcast of each presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. Replays of the presentations will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeli
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Lionbridge (Nasdaq: LIOX ) ... new, three-year master services agreement with a ... services that serve patients in approximately 100 ... the sole provider for translation of the ... training, human resources, legal, and corporate communications ...
(Date:12/14/2009)... - Results From a Survey Conducted by UCB Assessing ... Countries , , - A third of ... impacts their enjoyment of the festive season, ... shopping for gifts, preparing holiday ... difficult to do, - Nearly ...
(Date:12/11/2009)... Leuven, 10 December 2009 -- Researchers have discovered a new ... males. The more excess copies of a certain gene, the ... the X-chromosome; and it is suspected that it is the ... The results are being published in the American Journal ... by the group of Guy Froyen connected to VIB, a ...
(Date:12/11/2009)... DAVIS, Calif., Dec. 11 Marrone Bio ... its executive management team. Mr. Chris Hildreth joined ... and is responsible for expanding all commercial aspects ... development functions. Dr. Kin Sing (Ray) Lam joined ... leads the company,s development efforts in scaling its ...
Breaking Biology Technology:Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Amount of gene surplus determines severity of mental retardation in males 2Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3
... CFO of Thermage Inc. To, Drive Coapt,s ... ALTO, Calif., June 13 Coapt Systems, Inc.,developer of ... the,plastic, reconstructive and sports medicine markets, announced today the,appointment ... will also,serve as a member of the company,s Board ...
... IRIS trial, which established Gleevec as standard ... of care, - Study did not meet ... molecular responses with 800 vs. 400 mg ... optimize treatment benefit for individual patients, ...
... First Universal Theory of Humour Answers how and why ... Published today The Pattern,Recognition Theory of Humour, by ... Clarke explains how and why we find things,funny and ... societies,its fundamental role in the evolution of humans and ...
Other Biology Technology:Coapt Systems New CEO, Laureen DeBuono, to Fuel Company's Growth and Product Innovation 2Coapt Systems New CEO, Laureen DeBuono, to Fuel Company's Growth and Product Innovation 3Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 2Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 3Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 4Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 6Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 7Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 8Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 9Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 10Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 11Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 12Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 13Humour is Fundamental to our Success as a Species 2
(Date:12/15/2009)... mouse is a standard laboratory model organism, but ... techniques to analyze blood and blood-forming tissues in ... compact and easy-to-use laboratory resources from Cold Spring ... Mouse Hematology features step-by-step protocols for the ... bone marrow, and other hematopoietic tissues in the ...
(Date:12/14/2009)... renewable fuel that could help wean the nation from ... compared with gasoline, especially in winter, according to a ... production from both gasoline and E85, a blend of ... greater in warm sunny weather than during the cold ... sunlight contribute to ozone formation. But E85 produces different ...
(Date:12/14/2009)... Centre (INTA-CSIC) has shown that hydrogen cyanide, urea and ... most basic biological molecules can be obtained from the ... study, published in the journal Chemistry & Biodiversity ... early Earth. , "We have shown that when Prussian ... cyanide, a substance that could have played a fundamental ...
Breaking Biology News(10 mins):New source of classical techniques for blood-based studies in the laboratory mouse 2Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3Prussian blue linked to the origin of life 2arGEN X Concludes EUR 12 5 Million Series A Financing Round 6708 1arGEN X Concludes EUR 12 5 Million Series A Financing Round 6708 2arGEN X Concludes EUR 12 5 Million Series A Financing Round 6708 3arGEN X Concludes EUR 12 5 Million Series A Financing Round 6708 4Hennepin Regional Poison Center Designated as an Accredited Poison Control Center 62498 1Hennepin Regional Poison Center Designated as an Accredited Poison Control Center 62498 2Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 10970 1Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 10970 2
... which has had a huge impact on human culture across ... University has now identified the mutation causing this spectacular trait ... can be traced back to a common ancestor that lived ... research since this mutation also enhance the risk for melanoma. ...
... a time has earned acceptance in biology laboratories over the ... a tool to treat a variety of diseases if it ... discovered that antibiotics known as fluoroquinolones can make RNA interference ... The results will be published online this week in the ...
... Americans. From the comedic portrayal of "Mr. Limpet" by ... can talk, laugh and tell jokes--at least on television ... communicate? Researchers say, "Yes," in a paper published in ... . Further, the findings put human speech--and social communications ...
Other Biology News:The genetics of the white horse unraveled 2Class of antibiotics can enhance gene-silencing tool 2
... Rabbit polyclonal to Endothelin B ... Type B Receptor-Like Protein 2 (ETBR-LP-2) ... ESTs have been isolated from human ... Immunogen: Synthetic peptide (unfortunately, the ...
Mouse monoclonal [164-12-2] to Ampicillin ( Abpromise for all tested applications)....
... product contains 5 ml Dynabeads Epoxy (4.5 ... ether (epoxy) reactive groups. Ideal for coupling ... absorbed hydrophobically on initial coupling with covalent ... and sulphydryll groups (SH)) occurring within ...
... Normal;heading 1;heading 2;Many ... and experimental situations ... standard transfection and ... systems. ViraPower Lentiviral ...
Biology Products: